POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER).
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis and the citric acid cycle. |
| Excretion | Renal: >90% as potassium ions; feces: <10%; negligible biliary excretion. |
| Half-life | Terminal half-life approximately 0.5-1 hour for rapid distribution; clinical context: potassium is primarily intracellular, and serum half-life reflects redistribution rather than elimination. In renal impairment, half-life may prolong due to decreased excretion. |
| Protein binding | Minimal; approximately 0-10% bound to albumin; most potassium is free in plasma. |
| Volume of Distribution | Approximately 0.5-0.7 L/kg (total body water distribution); clinical meaning: potassium distributes primarily into intracellular space (98%), with Vd reflecting total body water. Higher Vd indicates larger intracellular stores. |
| Bioavailability | Oral: 85-100% (well absorbed); Intravenous: 100%. |
| Onset of Action | Intravenous: immediate (within seconds to minutes) for cardiac effects; oral: 30-60 minutes for serum potassium elevation. |
| Duration of Action | Intravenous: 2-4 hours for acute effects; oral: 4-6 hours. Continuous infusion maintains effect. Note: Duration depends on renal function and total body potassium deficit. |
| Molecular Weight | 74.55 |
10-20 mEq/hour intravenously, not to exceed 20 mEq/hour; maximum 200 mEq/day; adjust based on serum potassium levels.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: administer with caution, maximum 100 mEq/day. GFR <30 mL/min: avoid use or reduce dose to 50% of standard; monitor potassium closely. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose to 50-75% of standard, but evidence limited; monitor potassium levels. |
| Pediatric use | IV: 0.5-1 mEq/kg/dose, up to 20 mEq/dose, infused at 0.3-0.5 mEq/kg/hour; maximum 1 mEq/kg/hour. Adjust based on deficiency and monitoring. |
| Geriatric use | Initiate at low end of dosing range (5-10 mEq/hour IV); maximum 100 mEq/day; monitor renal function and potassium levels frequently due to age-related decline. |
| 1st trimester | Potassium chloride is essential for normal cellular function; use only if clearly needed and serum potassium monitored. No known teratogenicity. |
| 2nd trimester | Safe when used to correct hypokalemia; avoid excess potassium due to risk of hyperkalemia. |
| 3rd trimester | Use with caution near term; maternal hyperkalemia may cause fetal arrhythmias. Monitor serum potassium closely. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Placental transfer | Potassium crosses the placenta via active transport and passive diffusion. Fetal levels are regulated; maternal hyperkalemia can lead to fetal hyperkalemia and related effects. |
| Breastfeeding | Potassium is a normal constituent of breast milk. Exogenous potassium chloride is not expected to significantly increase milk levels. Use with caution in high doses due to potential for maternal hyperkalemia, which could affect the infant. |
| Lactation Rating | L1 - Safe |
| Teratogenic Risk | Potassium chloride is a physiologic electrolyte. No teratogenic effects are expected. There is no evidence of fetal risk at therapeutic doses; however, maternal hyperkalemia may cause fetal arrhythmias. In first trimester, no known structural teratogenicity. In second and third trimesters, maternal potassium imbalance can affect fetal cardiac conduction. |
| Fetal Monitoring | Monitor serum potassium levels, ECG for cardiac effects, and renal function. In pregnancy, monitor fetal heart rate during infusion due to risk of maternal hyperkalemia-induced fetal bradycardia. Assess for signs of hyperkalemia (e.g., muscle weakness, paresthesias). |
| Fertility Effects | No known adverse effects on fertility. Potassium chloride is essential for cellular function; imbalances may affect reproductive physiology, but therapeutic use is not associated with fertility impairment. |
■ FDA Black Box Warning
Concentrated potassium chloride solutions (≥2 mEq/mL) must be diluted before administration. Rapid intravenous administration of undiluted potassium chloride can cause fatal hyperkalemia and cardiac arrest.
| Serious Effects |
HyperkalemiaRenal failureSevere renal impairment with oliguria or anuriaConcurrent use of potassium-sparing diureticsSolid oral forms (not applicable to IV solution) in patients with gastrointestinal obstruction or delayed gastric emptying
| Precautions | Monitor serum potassium, glucose, and electrolyte levels frequently, Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia, Adjust rate of infusion based on clinical status and laboratory values, Avoid extravasation as may cause tissue necrosis |
| Food/Dietary | Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, avocados, dried fruits) to reduce risk of hyperkalemia. No known direct food-drug interactions with potassium chloride, but dietary potassium should be monitored. |
| Clinical Pearls | Potassium chloride 20 mEq in D5W is typically administered at a rate not exceeding 10 mEq/hour via peripheral line to avoid phlebitis; central line administration allows rates up to 20 mEq/hour with cardiac monitoring. Do not administer undiluted or via IV push due to risk of fatal hyperkalemia. Use with caution in patients with renal impairment, heart block, or digitalis toxicity. Incompatible with amiodarone, diazepam, and phenytoin. Monitor serum potassium and ECG during infusion. Correct hypomagnesemia before potassium repletion to prevent refractory hypokalemia. |
| Patient Advice | This medication is used to treat or prevent low potassium levels in your blood. · You will receive this medication through a vein (IV) in a hospital setting. · Inform your healthcare provider if you have kidney problems, heart disease, or are taking any other medications, especially diuretics or digoxin. · Report any symptoms of high potassium such as muscle weakness, irregular heartbeat, or tingling in the hands or feet. · Do not eat large amounts of potassium-rich foods (e.g., bananas, oranges, potatoes) without consulting your doctor. |
Loading safety data…